Opendata, web and dolomites

MEsHH SIGNED

DNA MEthylation for HPV-related disease among women living with HIV

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEsHH project word cloud

Explore the words cloud of the MEsHH project. It provides you a very rough idea of what is the project "MEsHH" about.

sa    623    living    overtreatment    strategies    lugol    burkina    collected    pyrosequencing    primary    16    positive    vili    615    18    mir    women    33    months    detection    31    visual    faso    self    capacity    regression    persistence    matching    carcinogenesis    hpv    assays    1238    progression    cervical    follow    enrolled    virus    cytology    thereby    alone    incident    lesion    shown    inspection    validation    colposcopy    ing       reported    poor    previously    screening    sensitivity    lesions    hpv16    prospective    epb41l3    bf    performance    hiv    genes    data    multiplex    histological    grade    cancer    swabs    meshh    dna    prevalent    relevance    background    africa    markers    acetic    intraepithelial    human    distinguish    mal    neoplasia    methylation    wlhiv    lacking    combination    tests    clinician    performed    predicting    referral    south    acid    cin2    predictive    stand    cin    coverage    cadm1    endocervical    iodine    specificity    negative    via   

Project "MEsHH" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908
website: www.idibell.cat

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-05   to  2020-09-04

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE ES (L'HOSPITALET DE LLOBREGAT) coordinator 158˙121.00

Map

 Project objective

Background: The current screening methods for cervical cancer screening among women living with HIV (WLHIV) have previously shown high sensitivity but poor specificity for the detection of high-grade cervical intraepithelial neoplasia (CIN2), resulting in over-referral for colposcopy and overtreatment of cervical lesions that may have low potential for progression to cancer. Methylation changes of human genes or HPV DNA have been reported early in carcinogenesis but their validation for predicting CIN among WLHIV is lacking. Objectives: Among 1238 WLHIV enrolled in Burkina Faso (BF; n=615) and South Africa (SA; n=623), the MesHH study aims to evaluate the performance of the DNA methylation of human genes (CADM1, MAL, MiR and EPB41L3) and HPV (HPV16/18/31/33) for the detection of prevalent and incident CIN2 compared to, or in combination with, other screening methods (visual inspection using acetic acid [VIA] or Lugol’s iodine [VILI], cytology and HPV DNA) and to evaluate the capacity of the DNA methylation markers to distinguish cervical lesion progression, persistence or regression at 16 months follow-up. Methods: The study will use endocervical swabs with matching histological data collected as part of a prospective study evaluating cervical cancer screening strategies among WLHIV in BF and SA. The DNA methylation assays for human genes (CADM1, MAL, MiR, EPB41L3) and HPV (HPV16/18/31/33) will be performed using pyrosequencing assays. Sensitivity, specificity, positive and negative predictive values for the detection of CIN2 will be estimated for the various DNA methylation markers, as stand-alone or multiplex tests. Relevance: Multiplex DNA methylation assays including a combination of human genes and HPV virus may have potential as primary screening for CIN2 among WLHIV. DNA methylation assays also have the potential to be performed using the same clinician- or self-collected sample used for cytology or HPV testing, thereby increasing screening coverage.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MESHH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MESHH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NeuroSens (2019)

Neuromodulation of Sensory Processing

Read More  

EPIC (2019)

Evolution of Planktonic Gastropod Calcification

Read More  

POMOC (2019)

Charles IV and the power of marvellous objects

Read More